RaySearch Laboratories Beheer

Beheer criteriumcontroles 3/4

De CEO RaySearch Laboratories is Johan Lof, benoemd in Jan2000, heeft een ambtstermijn van 24.83 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 9.76M, bestaande uit 66.2% salaris en 33.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 16.08% van de aandelen van het bedrijf, ter waarde € 98.98M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.1 jaar en 21.2 jaar.

Belangrijke informatie

Johan Lof

Algemeen directeur

SEK 9.8m

Totale compensatie

Percentage CEO-salaris	66.2%
Dienstverband CEO	24.8yrs
Eigendom CEO	16.1%
Management gemiddelde ambtstermijn	6.1yrs
Gemiddelde ambtstermijn bestuur	21.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Johan Lof's beloning veranderd ten opzichte van RaySearch Laboratories's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	SEK 175m
Jun 30 2024	n/a	n/a	SEK 151m
Mar 31 2024	n/a	n/a	SEK 101m
Dec 31 2023	SEK 10m	SEK 6m	SEK 82m
Sep 30 2023	n/a	n/a	SEK 64m
Jun 30 2023	n/a	n/a	SEK 53m
Mar 31 2023	n/a	n/a	SEK 22m
Dec 31 2022	SEK 7m	SEK 6m	SEK 24m
Sep 30 2022	n/a	n/a	-SEK 6m
Jun 30 2022	n/a	n/a	-SEK 38m
Mar 31 2022	n/a	n/a	-SEK 35m
Dec 31 2021	SEK 7m	SEK 6m	-SEK 47m
Sep 30 2021	n/a	n/a	-SEK 46m
Jun 30 2021	n/a	n/a	-SEK 50m
Mar 31 2021	n/a	n/a	-SEK 42m
Dec 31 2020	SEK 7m	SEK 6m	-SEK 9m
Sep 30 2020	n/a	n/a	SEK 24m
Jun 30 2020	n/a	n/a	SEK 43m
Mar 31 2020	n/a	n/a	SEK 74m
Dec 31 2019	SEK 8m	SEK 6m	SEK 50m
Sep 30 2019	n/a	n/a	SEK 64m
Jun 30 2019	n/a	n/a	SEK 85m
Mar 31 2019	n/a	n/a	SEK 84m
Dec 31 2018	SEK 8m	SEK 5m	SEK 79m
Sep 30 2018	n/a	n/a	SEK 118m
Jun 30 2018	n/a	n/a	SEK 104m
Mar 31 2018	n/a	n/a	SEK 103m
Dec 31 2017	SEK 9m	SEK 5m	SEK 118m

Compensatie versus markt: De totale vergoeding ($USD 893.46K ) Johan } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.42M ).

Compensatie versus inkomsten: De vergoeding van Johan is het afgelopen jaar met meer dan 20% gestegen.

CEO

Johan Lof (55 yo)

24.8yrs

Tenure

SEK 9,758,000

Compensatie

Dr. Johan Lof has been the Chief Executive Officer and President of Raysearch Laboratories AB (Publ) since 2000. Dr. Lof serves as the Chief Executive Officer of RaySearch Medical AB. Dr. Lof has been a Di...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Johan Lof	Founder	24.8yrs	SEK 9.76m	16.08% € 99.0m
Bjorn Hardemark	Deputy Chief Executive Officer	9.2yrs	SEK 3.54m	0.018% € 107.7k
Annika Henriksson	Acting Chief Financial Officer	1.3yrs	geen gegevens	geen gegevens
Kjell Eriksson	Head of Research & Chief Science Officer	9.2yrs	geen gegevens	0.047% € 287.3k
Petra Jansson	General Counsel	7.3yrs	geen gegevens	geen gegevens
Peter Kemlin	Director of Sales & Marketing	no data	geen gegevens	0.0041% € 25.1k
Tove Alteborg	Global Human Resource Manager	1.3yrs	geen gegevens	geen gegevens
Fredrik Lofman	Head of Machine Learning	4.8yrs	geen gegevens	0.0041% € 25.1k
Marc Mlyn	President & CEO of RaySearch Americas	2.8yrs	geen gegevens	geen gegevens

6.1yrs

Gemiddelde duur

50.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 27R is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Johan Lof	Founder	24.8yrs	SEK 9.76m	16.08% € 99.0m
Hans Wigzell	Independent Chairman of Board	20.5yrs	SEK 840.00k	geen gegevens
Carl Bergendal	Independent Director	24.8yrs	SEK 225.00k	3.39% € 20.9m
Radhe Mohan	Member of Scientific Advisory Board	21.8yrs	geen gegevens	geen gegevens
Anders Forsgren	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Anders Brahme	Member of Scientific Advisory Board	no data	geen gegevens	3.76% € 23.2m
David Jaffray	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Britta Wallgren	Independent Director	6.5yrs	SEK 300.00k	0.020% € 125.7k
Gunther Marder	Independent Director	2yrs	SEK 300.00k	0.20% € 1.3m

21.2yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 27R zijn ervaren en ervaren (gemiddelde ambtstermijn van 21.2 jaar).

RaySearch Laboratories Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

RaySearch Laboratories AB (publ) Announces CFO Changes

Deputy Chief Executive Officer recently sold €165k worth of stock

Henrik Bergentoft Leaves the Position as CFO for Raysearch

Founder recently sold €3.4m worth of stock

Founder recently sold €94k worth of stock

High number of new directors

Recent updates

Investor sentiment improves as stock rises 28%

RaySearch Laboratories AB (publ) to Report First Half, 2025 Results on Aug 07, 2025

RaySearch Laboratories AB (publ) to Report First Half, 2025 Results on Aug 08, 2025

RaySearch Laboratories AB (publ) Announces CFO Changes

Deputy Chief Executive Officer recently sold €165k worth of stock

RaySearch Laboratories AB (publ) to Report Q1, 2025 Results on May 09, 2025

Second quarter 2024 earnings released: EPS: kr1.79 (vs kr0.32 in 2Q 2023)

New minor risk - Share price stability

Investor sentiment improves as stock rises 20%

RaySearch to Present the Latest Advances in RayStation , RayCare and RayIntelligence At AAPM 2024

RaySearch Releases RayStation 2024B

RaySearch Laboratories AB (publ) Releases RayCare 2024A

Now 22% undervalued

Raysearch Laboratories AB (Publ) Apprves Ordinary Dividend for the Year 2023

First quarter 2024 earnings released: EPS: kr1.07 (vs kr0.51 in 1Q 2023)

Raysearch to Present the Latest Advances in Raystation, Raycare and Rayintelligence At Estro 2024

Full year 2023 earnings released: EPS: kr2.38 (vs kr0.69 in FY 2022)

New major risk - Revenue and earnings growth

RaySearch Laboratories AB (publ) Proposes an Extra Dividend for the Year Ended December 31, 2023, Payable on May 29, 2024

RaySearch Laboratories AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025

RaySearch Laboratories AB (publ) Releases Raystation 2024A

Third quarter 2023 earnings released: EPS: kr0.63 (vs kr0.29 in 3Q 2022)

RaySearch Laboratories AB (publ) to Report Q2, 2024 Results on Aug 16, 2024

RaySearch to Showcase Latest Innovations in Raystation, RayCare and RayIntelligence to Be Presented at ASTRO 2023

RaySearch Laboratories AB (Publ) to Showcase the Latest Software Innovations At Astro in San Diego, California, October 1-4

RaySearch Laboratories AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Investor sentiment improves as stock rises 16%

Second quarter 2023 earnings released: EPS: kr0.32 (vs kr0.58 loss in 2Q 2022)

RaySearch Laboratories AB (publ) to Report Q1, 2024 Results on May 17, 2024

RaySearch to Present the Latest Advances in Raystation, RayCare and RayIntelligence at AAPM 2023

RaySearch Laboratories AB (Publ) Announces the Release of the Latest Version of RayCare®, the Next Generation Oncology Information System

New minor risk - Share price stability

RaySearch Laboratories AB (publ) Releases Raystation 2023B

Raysearch Laboratories AB (Publ)'s RayCare in clinical use with CyberKnife at Lausanne University Hospital (CHUV) in Switzerland

Henrik Bergentoft Leaves the Position as CFO for Raysearch

New minor risk - Insider selling

Founder recently sold €3.4m worth of stock

New minor risk - Shareholder dilution

RaySearch Laboratories AB (publ) Announce to Exhibit Latest Software Innovations for Particle Therapy and BNCT at PTCOG 2023

First quarter 2023 earnings released

Founder recently sold €94k worth of stock

Full year 2022 earnings released: EPS: kr0.69 (vs kr1.38 loss in FY 2021)

RaySearch Laboratories AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

RaySearch Laboratories AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

Third quarter 2022 earnings released

High number of new directors

Raysearch Laboratories AB (Publ) Elects Günther Mårder as New Board Member

Second quarter 2022 earnings released

Raysearch Laboratories AB (Publ) Appoints Henrik Bergentoft as Cfo, Effective from November 15, 2022

RaySearch Laboratories AB (publ) Launches RayStation 12A

RaySearch to Exhibit the Latest Software Innovations for Particle Therapy at PTCOG 2022

RaySearch Laboratories AB (publ) Releases Latest Version of RayCare

Founder recently sold €1.9m worth of stock

First quarter 2022 earnings released

Raysearch Laboratories AB (Publ) Announces Raystation, Rayintelligence and Raycare to Be Presented At Estro 2022

Insufficient new directors

RaySearch Laboratories AB (publ) Announces Executive Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Founder recently sold €550k worth of stock

RaySearch AB (publ) Provides Cancer Clinics with User Configurable Workflows for Radiation Therapy

RayStation 11B Brings New Features for Adaptive Workflows, Brachytherapy, and Radiation Therapy with Ions

Third quarter 2021 earnings released

RaySearch Laboratories AB (publ) to Showcase Latest Innovations, RayIntelligence and RayCare at ESTRO 2021

Second quarter 2021 earnings released

Insufficient new directors

RaySearch Laboratories AB (Publ) Announces RayStation 9 Granted Regulatory Clearance in China

Raysearch Announces the Release of A New Version of Raycare®, the Next-Generation Oncology Information System

Raysearch Laboratories Announces the Release of Raystation® 11A

Raysearch Laboratories AB (Publ) Provides Earnings Guidance for 2021